• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Natural Products - NF-kB Pathway Inhibitors
You are here: Product Lines > Natural Products / Antibiotics > Natural Products > Natural Products - Signal Transduction Pathway Modulators > Natural Products - NF-kB Pathway Inhibitors
Toolbar - View Selection
 
 Items 20-31 of 31 Page 2 of 2 Select Page: << 1 2   
ALX-350-289 Revised 18-Nov-08
10Z-Hymenialdisine
Add to Clipboard
SYNONYMS 4-(2-Amino-4-oxo-2-imidazolin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Protein Kinase Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-289-C500   500 µg 190.00 USD Add To Cart
ALX-350-289-M001   1 mg 340.00 USD Add To Cart
Product Specification
FORMULA: C11H10BrN5O2
MW: 324.1
CAS NUMBER: 82005-12-7
SOURCE/HOST: Isolated from sponge Axinella carteri.
PURITY: ≥97% (HPLC)
APPEARANCE: Yellow needles.
SOLUBILITY: Soluble in DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
HANDLING: Protect from light.
HAZARD: TOXIC.
IDENTITY: Identity determined by 1H- NMR and MS.

Product Description
Originally isolated from the sponges Axinella verrucosa and Acantella aurantiaca. Potent inhibitor of mitogen-activated protein kinase kinase-1 (MEK-1) (IC50=6nM). Blocks the in vivo phosphorylation of the microtubule-binding protein tau at sites that are hyperphosphorylated by glycogen synthase kinase-β (GSK-3β) and CDK5/p35 in Alzheimer’s disease. Inhibitor of DNA damage checkpoint at G2 phase (IC50=6µM), cyclin-dependent kinases CDK1/cyclin B (IC50=22nM), CDK2/cyclin A (IC50=70nM), CDK2/cyclin E (IC50=40nM), CDK4/cyclin D1 (IC50=600nM), CDK5/p25 (IC50=28nM), GSK-3β (IC50=10nM), and casein kinase 1 (CK1) (IC50=35nM). Inhibitor of NF-κB activation and of various pro-inflammatory cytokines such as IL-1, IL-2 (IC50=2.4µM), IL-6, IL-8, TNF-α (IC50=1.4µM) and nitric oxide (NO) (IC50=0.8µM) in a variety of cell lines.
Product Specific Literature References
Isolation and x-ray crystal structure of a novel bromo-compound from two marine sponges: G. Cimino, et al.; Tetrahedron Lett. 23, 767 (1982)
Bioactive alkaloids from the tropical marine sponge Axinella carteri: A. Supriyono, et al.; Z. Naturforsch. [C] 50, 669 (1995) Abstract
The natural product hymenialdisine inhibits interleukin-8 production in U937 cells by inhibition of nuclear factor-kappaB: J.J. Breton & M.C. Chabot-Fletcher; J. Pharmacol. Exp. Ther. 282, 459 (1997) Abstract; Full Text
Inhibition of NFkappaB-mediated interleukin-1beta-stimulated prostaglandin E2 formation by the marine natural product hymenialdisine: A. Roshak, et al.; J. Pharmacol. Exp. Ther. 283, 955 (1997) Abstract; Full Text
Inhibition of interleukin-1-induced proteoglycan degradation and nitric oxide production in bovine articular cartilage/chondrocyte cultures by the natural product, hymenialdisine: A.M. Badger, et al.; J. Pharmacol. Exp. Ther. 290, 587 (1999) Abstract; Full Text
Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent: L. Meijer, et al.; Chem. Biol. 7, 51 (2000) Abstract
Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine: D. Curman, et al.; J. Biol. Chem. 276, 17914 (2001) Abstract; Full Text
An investigation of cell proliferation and soluble mediators induced by interleukin 1beta in human synovial fibroblasts: comparative response in osteoarthritis and rheumatoid arthritis: H. Inoue, et al.; Inflamm. Res. 50, 65 (2001) Abstract
Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1): D. Tasdemir, et al.; J. Med. Chem. 45, 529 (2002) Abstract
Inhibition of cytokine production by hymenialdisine derivatives: V. Sharma, et al.; J. Med. Chem. 47, 3700 (2004) Abstract
Further Categories Containing This Product:
CDK & Cyclin Inhibitors • MAPK Pathway Inhibitors • Natural Products - NF-kB Pathway Inhibitors • NF-kB Pathway Inhibitors • Natural Products for Cell Cycle Research • Alkaloids • Natural Products - Nitric Oxide Pathway Modulators • DNA Damage Checkpoint Other Products • GSK-3 Inhibitors • Marine Natural Products
 
 
ALX-350-298 Revised 03-Apr-08
Betulinic acid (~95%)
Add to Clipboard
SYNONYMS 3β-Hydroxy-20(29)-lupaene-28-oic acid
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Antitumor Reagents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-298-M100   100 mg 55.00 USD Add To Cart
ALX-350-298-M500   500 mg 180.00 USD Add To Cart
ALX-350-298-G001   1 g 290.00 USD Add To Cart
Inquire
Product Specification
FORMULA: C30H48O3
MW: 456.7
CAS NUMBER: 472-15-1
SOURCE/HOST: Isolated from Platanus acerifolia (plane tree) bark.
PURITY: ≥95% (HPLC)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C

Product Description
Antitumor and anti-HIV agent. Induces apoptosis by activating mitochondrial permeability transition (MPT). Inhibits NF-κB activation and NF-κB-regulated gene expression induced by carcinogens and inflammatory stimuli. Decreases expression of Bcl-2 and cyclin D1. Potent proteasome activator.
Product Specific Literature References
Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids: T. Fujioka, et al.; J. Nat. Prod. 57, 243 (1994) Abstract
Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis: E. Pisha, et al.; Nat. Med. 1, 1046 (1995) Abstract
Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents: Y. Kashiwada, et al.; J. Med. Chem. 39, 1016 (1996) Abstract
Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors: S. Fulda, et al.; Cancer Res. 57, 4956 (1997) Abstract
Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives: F. Hashimoto, et al.; Bioorg. Med. Chem. 5, 2133 (1997) Abstract
Betulinic acid induces apoptosis in human neuroblastoma cell lines: M.L. Schmidt, et al.; Eur. J. Cancer 33, 2007 (1997) Abstract
Induction of p53 without increase in p21WAF1 in betulinic acid-mediated cell death is preferential for human metastatic melanoma: M. Rieber & M. Strasberg Rieber; DNA Cell Biol. 17, 399 (1998) Abstract
Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid: S. Fulda, et al.; J. Biol. Chem. 273, 33942 (1998) Abstract; Full Text
Betulinic acid inhibits aminopeptidase N activity: M.F. Melzig & H. Bormann; Planta Med. 64, 655 (1998) Abstract
Correspondence re: S. Fulda et al., Betulinic acid triggers CD95 (Apo1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res., 57: 4956, 1997: M. Rieber & M. Strasberg Rieber; Cancer. Res. 58, 5876 (1998) Abstract
Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells: S. Fulda, et al.; Int. J. Cancer 82, 435 (1999) Abstract
Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing: W. Wick, et al.; J Pharmacol. Exp. Ther. 289, 1306 (1999) Abstract; Full Text
Effects of betulinic acid alone and in combination with irradiation in human melanoma cells: E. Selzer, et al.; J. Invest. Dermatol. 114, 935 (2000) Abstract
Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9: Y. Takada & B.B. Aggarwal; J. Immunol. 171, 3278 (2003) Abstract
Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection: R.H. Cichewicz & S.A. Kouzi; Med. Res. Rev. 24, 90 (2004), Review Abstract
Betulinic acid-induced apoptosis in leukemia cells: H. Ehrhardt, et al.; Leukemia 18, 1406 (2004) Abstract
Betulinic acid and its derivatives: a review on their biological properties: P. Yogeeswari & D. Sriram; Curr. Med. Chem. 12, 657 (2005), Review Abstract
Betulinic acid decreases expression of bcl-2 and cyclin D1, inhibits proliferation, migration and induces apoptosis in cancer cells: W. Rzeski, et al.; Naunyn Schmiedebergs Arch. Pharmacol. 374, 11 (2006) Abstract
Activation and inhibition of the proteasome by betulinic acid and its derivatives: L. Huang, et al.; FEBS Lett. 581, 4955 (2007) Abstract
Further Categories Containing This Product:
CDK & Cyclin Inhibitors • NF-kB Pathway Inhibitors • Other Natural Products - DNA Regulation / Transcription • Natural Products - NF-kB Pathway Inhibitors • MPTP [Mitochondrial Transition Pore] / Related Products • Natural Products - Anti-inflammatory Agents • Natural Products - Antiviral / anti-HIV Agents • Antitumor Agents (Apoptosis Inducers) • Ubiquitin & Proteasome Other Products • Natural Products - Apoptosis Inducers & Inhibitors • HIV / AIDS / Related Products
 
 
ALX-350-301 Revised 14-May-07
Oxaspirodion
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - NF-kB Pathway Inhibitors
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-301-MC05   0.5 mg 290.00 USD Add To Cart
Product Specification
FORMULA: C13H14O5
MW: 250.3
SOURCE/HOST: Isolated from Chaetomium subspirale.
APPEARANCE: Orange to brown oil.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Mixture of 4 non-separable isomers. Inhibits TNF-α expression (IC50=2.5µg/ml). Exhibits no antibacterial and antifungal activities up to 100µg/disk in the standard disk assay. Weak cytotoxic properties against tumor cells. Inhibition of the TNF-α promoter activity is caused by an inhibition of the phosphorylation of the ERK1/2 kinases. In addition, oxaspirodion inhibits the activation of the transcription factor NF-κB, which is involved in the inducible expression of many proinflammatory genes.
Product Specific Literature References
Oxaspirodion, a new inhibitor of inducible TNF-alpha expression from the Ascomycete chaetomium subspirale. Production, isolation and structure elucidation: J. Rether, et al.; J. Antibiot. 57, 493 (2004) Abstract
Inhibition of inducible TNF-alpha expression by oxaspirodion, a novel spiro-compound from the ascomycete Chaetomium subspirale: J. Rether, et al.; Biol. Chem. 385, 829 (2004) Abstract
Further Categories Containing This Product:
TNF-alpha & TNF Receptors Other Products • NF-kB Pathway Inhibitors
 
 
ALX-350-308 Revised 03-Apr-08
3-O-Acetyl-β-boswellic acid
Add to Clipboard
SYNONYMS AβBA
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Antitumor Reagents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-308-M001   1 mg 45.00 USD Add To Cart
ALX-350-308-M005   5 mg 180.00 USD Add To Cart
Product Specification
FORMULA: C32H50O4
MW: 498.8
CAS NUMBER: 5968-70-7
SOURCE/HOST: Isolated from Boswellia sp.
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in acetone, dimethyl formamide, DMSO, dichloromethane, 100% ethanol or methanol; sparingly soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Shows antitumor and anti-inflammatory activities. Potent non-redox, non-competitive 5-lipoxygenase and topoisomerase I and IIa inhibitor leading to apoptosis. 10-100 times more potent than natural boswellic acid.
Product Specific Literature References
Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers: V. Sterk, et al.; Planta Med. 70, 1155 (2004) Abstract
Effects of Boswellia serrata in mouse models of chemically induced colitis: P.R. Kiela, et al.; Am. J. Physiol. Gastrointest. Liver. Physiol. 288, G798 (2005) Abstract
Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo: T. Syrovets, et al.; J. Biol. Chem. 280, 6170 (2005) Abstract; Full Text
Induction of central signalling pathways and select functional effects in human platelets by beta-boswellic acid: D. Poeckel, et al.; Br. J. Pharmacol. 146, 514 (2005) Abstract
Boswellic acids: biological actions and molecular targets: D. Poeckel & O. Werz; Curr. Med. Chem. 13, 3359 (2006), Review Abstract
Further Categories Containing This Product:
Natural Products - NF-kB Pathway Inhibitors • Natural Products - Protein Kinase Inhibitors • Lipoxygenases / Related Products • NF-kB Pathway Inhibitors • Natural Products - Anti-inflammatory Agents • Antitumor Agents (Apoptosis Inducers) • Natural Products - Topoisomerase Inhibitors • Natural Products - Apoptosis Inducers & Inhibitors
 
 
ALX-350-310 Revised 03-Apr-08
3-O-Acetyl-11-keto-β-boswellic acid
Add to Clipboard
SYNONYMS AKβBA
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Antitumor Reagents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-310-M005   5 mg 130.00 USD Add To Cart
Product Specification
FORMULA: C32H48O5
MW: 512.7
CAS NUMBER: 67416-61-9
SOURCE/HOST: Isolated from Boswellia serrata.
PURITY: ≥99% (HPLC, NMR)
APPEARANCE: White to off-white solid.
SOLUBILITY: Soluble in acetone, dichloromethane, diethyl ether or DMSO.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C
USE/STABILITY: Stock solutions are stable for up to 3 months when stored at -20°C.
HANDLING: Protect from light.
HAZARD: MAY BE CARCINOGENIC. HARMFUL.

Product Description
Shows antitumor and anti-inflammatory activities. Potent non-redox, noncompetitive 5-lipoxygenase and topoisomerase I and IIa inhibitor leading to apoptosis. 10-times more potent than 3-O-acetyl-β-boswellic acid (Prod. No. ALX-350-308). Exhibits in vivo efficacy in tumor growth and inhibition.
Product Specific Literature References
Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I: R.F. Hoernlein, et al.; J. Pharmacol. Exp. Ther. 288, 613 (1999) Abstract; Full Text
Boswellic acids activate p42(MAPK) and p38 MAPK and stimulate Ca(2+) mobilization: A. Altmann, et al.; BBRC 290, 185 (2002) Abstract
Coupling of boswellic acid-induced Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes: A. Altmann, et al.; Br. J. Pharmacol. 141, 223 (2004) Abstract; Full Text
Inhibition of IkappaB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo: T. Syrovets, et al.; J. Biol. Chem. 280, 6170 (2005) Abstract; Full Text
Boswellic acids: biological actions and molecular targets: D. Poeckel & O. Werz; Curr. Med. Chem. 13, 3359 (2006), Review Abstract
Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis: C. Anthoni, et al.; Am. J. Physiol. Gastrointest. Liver Physiol. 290, G1131 (2006) Abstract
Potentiation of antinociceptive effect of NSAIDs by a specific lipooxygenase inhibitor, acetyl 11-keto-beta boswellic acid: M. Bishnoi, et al.; Indian J. Exp. Biol. 44, 128 (2006) Abstract
Related Products
Further Categories Containing This Product:
Natural Products - Protein Kinase Inhibitors • Lipoxygenases / Related Products • NF-kB Pathway Inhibitors • Natural Products - Anti-inflammatory Agents • Antitumor Agents (Apoptosis Inducers) • Natural Products - Topoisomerase Inhibitors • Natural Products - NF-kB Pathway Inhibitors • Natural Products - Apoptosis Inducers & Inhibitors
 
 
ALX-350-333 Revised 05-Apr-08
Harpagoside
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Anti-inflammatory Agents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-333-M005   5 mg 90.00 USD Add To Cart
ALX-350-333-M025   25 mg 360.00 USD Add To Cart
Product Specification
FORMULA: C24H30O11
MW: 494.5
CAS NUMBER: 19210-12-9
SOURCE/HOST: Isolated from Scrophularia ningpoensis Hemsl (Figwort).
PURITY: ≥98% (HPLC)
APPEARANCE: White to off-white powder.
SOLUBILITY: Soluble in methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Anti-inflammatory and anti-diabetic compound. Suppresses LPS-induced inducible nitric oxide synthase (iNOS; NOS II) and cyclooxygenase-2 (COX-2) expression through inhibition of NF-κB activation.
Product Specific Literature References
Antiinflammatory effects of different extracts and harpagoside isolated from Scrophularia frutescens: L. D. Garcia, et al.; Farmaco. 51, 443 (1996) Abstract
Physicochemical properties of harpagoside and its in vitro release from Harpagophytum procumbens extract tablets: S. Chrubasik, et al.; Phytomedicine 6, 469 (2000) Abstract
Scropolioside-D2 and harpagoside-B: two new iridoid glycosides from Scrophularia deserti and their antidiabetic and antiinflammatory activity: B. Ahmed, et al.; Biol. Pharm. Bull. 26, 462 (2003) Abstract; Full Text
Downregulation of iNOS expression in rat mesangial cells by special extracts of Harpagophytum procumbens derives from harpagoside-dependent and independent effects: M. Kaszkin, et al.; Phytomedicine 11, 585 (2004) Abstract
High anti-inflammatory activity of harpagoside-enriched extracts obtained from solvent-modified super- and subcritical carbon dioxide extractions of the roots of Harpagophytum procumbens: M. Gunther, et al.; Phytochem. Anal. 17, 1 (2006) Abstract
Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation: T.H. Huang, et al.; J. Ethnopharmacol. 104, 149 (2006) Abstract
Simultaneous determination of harpagoside and cinnamic acid in rat plasma by high-performance liquid chromatography: application to a pharmacokinetic study: P. Li, et al.; Anal. Bioanal. Chem. 389, 2259 (2007) Abstract
Further Categories Containing This Product:
NOS Inhibitors (NOS Induction & Enzyme Activity) • NF-kB Pathway Inhibitors • COX Other Products • Natural Products - Nitric Oxide Pathway Modulators • Natural Products - NF-kB Pathway Inhibitors
 
 
ALX-385-011 Revised 05-Apr-08
(±)-Hesperetin
Add to Clipboard
SYNONYMS (±)-3',5,7-Trihydroxy-4'-methoxyflavanone
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Flavanones
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-385-011-G001   1 g 21.00 USD Add To Cart
Product Specification
FORMULA: C16H14O6
MW: 302.3
CAS NUMBER: 520-33-2
MERCK INDEX: 14: 4670
PURITY: ≥95% (HPLC)
APPEARANCE: Off-white to yellow powder.
SOLUBILITY: Soluble in 100% ethanol; slightly soluble in water.
SHIPPING: AMBIENT
LONG TERM STORAGE: +4°C

Product Description
Antioxidant flavonoid. Induces G1-phase cell cycle arrest. Anti-inflammatory. Suppresses NF-κB activation. Reduces cholesterol biosynthesis. Inhibits lipid peroxidation. Neuroprotective against neuronal oxidative damage.
Product Specific Literature References
Structure-antioxidant activity relationships of flavonoids and phenolic acids: C.A. Rice-Evans, et al.; Free Radical Biol. & Med. 20, 933 (1996), (Review) Abstract
Lipid-lowering efficacy of hesperetin metabolites in high-cholesterol fed rats: H. K. Kim, et al.; Clin. Chim. Acta 327, 129 (2003) Abstract
Antioxidant and neuroprotective effects of hesperidin and its aglycone hesperetin: J. Cho; Arch. Pharm. Res. 29, 699 (2006) Abstract
Modulation of the age-related nuclear factor-kappaB (NF-kappaB) pathway by hesperetin: J. Y. Kim, et al.; Aging Cell 5, 401 (2006) Abstract
Hesperetin Induced G1-Phase Cell Cycle Arrest in Human Breast Cancer MCF-7 Cells: Involvement of CDK4 and p21: E.J. Choi; Nutr. Cancer 59, 115 (2007) Abstract
Further Categories Containing This Product:
Cell Cycle Blockers & Inhibitors / Related Products • Active Substances from Fruit and Vegetables • NF-kB Pathway Inhibitors • Natural Products - Antioxidants • Natural Products - Anti-inflammatory Agents • Natural Products - NF-kB Pathway Inhibitors
 
 
ALX-385-012 Revised 19-Nov-07
Myricetin
Add to Clipboard
SYNONYMS 3,3',4',5,5',7-Hexahydroxyflavone
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Flavonols
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-385-012-M010   10 mg 35.00 USD Add To Cart
ALX-385-012-M050   50 mg 140.00 USD Add To Cart
Product Specification
FORMULA: C15H10O8
MW: 318.2
CAS NUMBER: 529-44-2
MERCK INDEX: 14: 6332
RTECS: LK8646000
PURITY: ≥97%
APPEARANCE: Light yellow-green crystals.
SOLUBILITY: Soluble in alcohol; slightly soluble in water (warm); insoluble in acetic acid.
SHIPPING: AMBIENT
LONG TERM STORAGE: +20°C
HANDLING: Protect from light.

Product Description
Antioxidant flavonoid. Has antitumor and chemopreventive properties. Anti-inflammatory. Inhibits NF-κB activation. 
Product Specific Literature References
Structure-antioxidant activity relationships of flavonoids and phenolic acids: C.A. Rice-Evans, et al.; Free Radical Biol. & Med. 20, 933 (1996), (Review) Abstract
Biological effects of myricetin: K. C. Ong & H. E. Khoo; Gen. Pharmacol. 29, 121 (1997), (Review) Abstract
In vitro cytotoxicity of glyco-S-nitrosothiols. a novel class of nitric oxide donors: H. Babich & H.L. Zuckerbraun; Toxicol. In Vitro 15, 181 (2001) Abstract
Suppression of TNFalpha-mediated NFkappaB activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells: S. H. Tsai, et al.; J. Cell Biochem. 74, 606 (1999) Abstract
Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells: C.H. Ko, et al.; Mol. Cancer Ther. 4, 281 (2005) Abstract
Mitochondrial-dependent, reactive oxygen species-independent apoptosis by myricetin: roles of protein kinase C, cytochrome c, and caspase cascade: C.H. Ko, et al.; Biochem. Pharmacol. 69, 913 (2005) Abstract
Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity: J. Lu, et al.; Cancer Res. 66, 4410 (2006) Abstract
Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1: K.W. Lee, et al.; Carcinogenesis 28, 1918 (2007) Abstract